



TapImmune Inc. ("TapImmune" "TPIV") is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. TPIV technologies are based on an understanding of the function of a protein "pump" known as TAP. **Transporters Associated with Antigen Processing (TAP)** are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. These markers are required for the effective recognition and destruction of cancer cells and virus infected cells by the immune system. A wide variety of metastatic cancers evade destruction by the immune system due to absent or insufficient amounts of TAP, making the tumors unrecognizable.

TPIV's lead product, the **TAP vaccine** performs a **key step** in moving characteristic markers called antigens to the surfaces of cells allowing the recognition and killing of cancer cells by the immune system. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected.

Clinical studies to date have identified a large number of cancers deficient in TAP including but not limited to HPV related cancers such as **melanoma, lung, prostate, breast** and **ovarian cancer**. **TapImmune** believes these tumors would be responsive to the TAP therapeutic vaccine. In preclinical trials for melanoma and lung carcinoma, *animal survival rates of 70% were achieved* using TAP vaccine therapy and *100% survival* when TAP was administered ex-vivo.

TPIV's vaccine has shown effective restoration of TAP and the TAP molecule also works as an adjuvant or to enhance targeted vaccines against infectious diseases. Including TAP in the much studied Smallpox Vaccine, its **potency was increased by 100-1000 times**. TPIV is currently developing models for the application of this technology for some of the most important societal pathogens.

This is a new paradigm in the treatment of infectious disease and could significantly advance the development of new vaccines as well as improve those that already exist.

Recent Highlight Announcements Include:

TB Vaccine development program with Aeras Global TB Foundation – Jan 2010

Breast Cancer Clinical Program partnering with Mayo Clinic – June 2010

SmallPox vaccine program with Mayo Clinic – Aug 2010

World Class Advisory Board – Sept 2010

The global vaccine market is expected to grow from \$13 billion in 2007 to \$21 billion in 2010.

The TapImmune cancer vaccine is a stand alone product that also compliments the traditional area of immunotherapeutics including: chemotherapy, radiation and current cancer vaccine candidates.

TapImmune's Infectious disease vaccine adjuvant can make vaccines 100 times more effective!

In The Media



Developments to Watch:
Waking Up a Sleeping Anticancer Gene



Attacking Cancer - an Immune-Boosting Vaccine



ABC News - Business Now TV

Visit www.TapImmune.com to view and read these Media Releases



OTCBB – TPIV

Shares Authorized - 150 Million
Outstanding Shares: 40,000,000
Free Trading Float = 18 Million
Management Ownership: 15%

Website: www.TapImmune.com

Contact:
Email: Info@TapImmune.com
Tel: (206) 336-5560

TapImmune Inc.
2815 Eastlake Avenue East
Suite 300
Seattle WA 98102

